Daniel Drucker, MD, recent winner of our Lifetime Achievement Laureate Award, the top honors in the field, shares his story as one of the pioneers in advancing next-generation anti-obesity medications such as Ozempic in a new video series on obesity care.
Drucker, who is a senior investigator at the Lunenfeld-Tanenbaum Research Institute, Sinai Health, and a university professor in the Department of Medicine at the University of Toronto’s Temerty Faculty of Medicine in Ontario, Canada, describes the discovery of glucagon-like peptides (GLP-1s) for treating obesity as a team effort and looks forward to future developments in obesity research.
Watch the four-part video series:
The Society’s ongoing “Talking Obesity” video series features our experts discussing the latest in obesity research and care. Topics include the discovery of the latest class of anti-obesity medications, how these medications have been lifesaving for people with obesity and diabetes and improving access to care. Stay tuned for our next series on pediatric health.
Additional obesity-related resources can be found on our Focus on Obesity page: https://bit.ly/3yV6Ihc
Loading ...